Early drug development Conference // Drug Repurposing

Early drug development Conference

Europe s largest early

The two day conference (28 – 29 October 2014), initiated by Auxiliis, will feature presentations from academia, regulatory authorities, pharmaceutical industry, and contract research organisations.

The awareness of the value of new medicines for children and clinical research with children has increased over the past decades, partially as a result of US and EU legislation. However, Paediatric clinical practice has changed less than had been hoped for as a result of this legislation. The initial enthusiasm for the effects of legislative attempts to increase paediatric drug development has been replaced by a more realistic assessment. Breakthrough therapeutic innovations have been introduced in both adult and paediatric medicine. New successful therapies have been developed for example for cystic fibrosis, for rare metabolic diseases, and others. However, they were not triggered by paediatric legislation.

In addition, while academic medical research is essential and its value recognized, it seldom results in transition from bench to bedside without commercial involvement. The value of commercialization in the drug development process has often been underestimated. The organizers of this meeting consider it desirable for public perception and discussion in the media as well as in academia to become more open-minded about the need for and value of commercial translational research.

Pediatric Drug Development

The enthusiasm associated with paediatric drug development legislation was driven by the generally recognized need for more and better pediatric drugs and devices. What then is the way forward?

  • This conference will provide an update on both state-of-the-art methodology as well as the many operational challenges in paediatric clinical research.
  • The faculty will represent different groups that all have a stake in paediatric drug development and paediatric research including academic and commercial researchers, patient advocates, regulatory representatives, and companies devoted to improving pediatric therapy.
  • The conference will be highly interactive in order to allow a hands-on exchange of ideas and experiences.
  • The conference aims to re-evaluate what is needed for more effective and efficient progresses in the development of drugs for both paediatric and rare diseases.

You might also like

Drug war against blacks

by instigator

An exerpt:
Police cars and cops with military assault weaponry swept through the sleepy farming hamlet of Tulia, Texas on July 23, 1999. They were supposedly looking for drug offenders to fill the nearby prison. At the end of the day, 40 of the town's 246 black residents – mostly young men – were behind bars.
Many of those arrested couldn't afford legal help, but they knew that what had happened was wrong. In a small, predominantly white town of 5,000 with no significant drug problems, the arrest of 40 black residents – along with only one white and one Hispanic – was a clear message of racial intolerance

Drug use down by half in Portugal

by Antiderivative

Ten Years After Decriminalization, Drug Abuse Down by Half in Portugal
Drug warriors often contend that drug use would skyrocket if we were to legalize or decriminalize drugs in the United States. Fortunately, we have a real-world example of the actual effects of ending the violent, expensive War on Drugs and replacing it with a system of treatment for problem users and addicts.
Ten years ago, Portugal decriminalized all drugs. One decade after this unprecedented experiment, drug abuse is down by half:
Health experts in Portugal said Friday that Portugal’s decision 10 years ago to decriminalise drug use and treat addicts rather than punishing them is an experiment that has worked


by ---

21. Fighting parasitic diseases, such as saving the lives of 7 million children from going blind from the river blindness and rescued many others from guinea worm and other tropical diseases.
22. Promoting investment in developing countries ­promoting entrepreneurship and self-reliance, industrial cooperation and technology transfer and cost-effective, ecologically-sensitive industry.
23. Reducing the effects of natural disasters ­early warning system, which utilizes thousands of surface monitors as well as satellites, has provided information for the dispersal of oil spills and has predicted long-term droughts

Plan B goes OTC for those aged 18 and over.(over the counter)(drug approvals): An article from: Skin & Allergy News
Book (Thomson Gale)

Inform Genomics and Translational Drug Development (TD2) Announce ..  — MarketWatch
.. LLC (TD2) based in Scottsdale, Arizona, today announced a strategic collaboration leveraging Inform Genomics' proprietary technology platform and analytic capabilities to biopharmaceutical companies through TD2's oncology drug development services.

2 Boxes! - Green Coffee 1000 Gold Leptin, 100% Original Product. Us Seller Reduces Appetite and Stimulates the Body to Burn Fat, Lose Weight Quickly and Responsibly Weight Loss Coffee
Single Detail Page Misc ()
  • Leptin Green Coffee 1 Gold is the successor of the widely successful Green Coffee 800. Green Coffee 1 features an updated formula and double action ingredients...
RESPeRATE RESPeRATE Ultra - Blood Pressure Lowering Device For Non-Drug Hypertension Reduction
Health and Beauty (RESPeRATE)
  • RESPeRATE is the only non-drug therapy cleared by the FDA for the treatment of high blood pressure and the reduction of stress
  • lower high blood pressure within weeks with only a few 15 minutes sessions per week
  • Clinically proven in 10 different clinical trials to lower blood pressure
  • Recommended by doctors and approved for reimbursement by FSA and HSA plans.
  • RESPeRATE is a one-time investment that gets you the desired results with no drugs and no side effects. No medical prescription required
Web site to help seniors get drug-cost assistance. (Free Service).: An article from: Clinical Psychiatry News
Book (International Medical News Group)
INTERNATIONAL MONETARY FUND The United States Economy: Performance and Issues